Every 8-K that GLOBAL INNOVATIVE PLATFOM (GIPL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GIPL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GIPL filings page.
Global Innovative Platforms Inc. issued a shareholder update highlighting progress at VetBreath Analytics across funding, regulation, science, and partnerships. The company reports having enough capital to operate through the end of 2026 after completing a Regulation A offering in March 2026.
The update notes a 15c2-11 application submitted to FINRA on June 12, 2026, an eight-month heartworm study begun April 1, 2026, and development of four additional parasite breath signatures. Revenue for the six months ended March 31, 2026 was $136,500, supported by a collaboration generating about $15,000–$18,000 per month.
Global Innovative Platforms also expanded its Board and Strategic Advisory Board with experienced commercial, governance, and veterinary leaders, added new clinical development expertise, joined and won a Plug and Play incubator pitch competition, and launched a high-volume sample collection collaboration with Big Dog Ranch Rescue.
Global Innovative Platforms Inc. expanded its board of directors from one to four members, effective April 1, 2026, and appointed Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer as directors.
The new directors bring experience in animal health research, legal practice, healthcare operations, business development, and partnership management, aligning with the company’s focus on innovative breath-based diagnostics for animal health. The company states there are no family relationships, appointment-related arrangements, or related-party transactions requiring disclosure, and that any committee assignments or director compensation will be detailed in a later filing.
Global Innovative Platforms Inc. posted an updated investor presentation on its website on March 31, 2026. The presentation, which is furnished as Exhibit 99.1, is available under the Investor Relations section of www.vetbreath.com.
The company states that the information in this report and Exhibit 99.1 is furnished under Regulation FD, not filed, and is therefore not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings.
Global Innovative Platforms Inc. reported that it has posted an updated investor presentation and shared preliminary scientific results on its VOCAM Plus breath-analysis technology for canine heartworm detection. The company used artificial intelligence and multivariate statistical tools to analyze breath samples from dogs with and without confirmed heartworm and found measurable differences between infected and non‑infected animals.
The study suggests a consistent breath VOC profile associated with heartworm, including in many samples classified as early-stage infection, a phase where current antigen tests cannot yet detect disease for roughly the first six months. In an internal self-prediction test of its model, there was only one misclassification, in which an early heartworm sample was labeled as mature. When the model was applied to the full dataset, trimmed samples did not incorrectly fall into any of the three modeled states. The company plans to continue testing and confirming these early but encouraging findings.
Global Innovative Platforms Inc. (GIPL) filed an 8-K announcing two developments. The company entered into an agreement with a global animal health company to evaluate and validate its proprietary VOCAM Plus breathomics diagnostic technology for detecting heartworm disease in dogs. The company will supply VOCAM Plus units and related support services for this evaluation, with the full agreement to be filed with the next Form 10-K.
The Board changed auditors. On November 3, 2025, it dismissed M. S. Madhava Rao, Chartered Accountant, and appointed CNGSN & Associates LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025. The prior auditor’s reports for fiscal years 2024 and 2023 contained no adverse opinions or disclaimers, and the company reports no disagreements or reportable events. A letter from the former auditor dated November 6, 2025 is filed as Exhibit 16.1.